Coronado Biosciences to Participate in Citi's 8th Annual Biotech Conference

Coronado Biosciences logo

BURLINGTON, Mass., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that Dr. Harlan F. Weisman, Coronado's Chairman and CEO, will participate in Citi's 8th Annual Biotech Conference. The conference will be held at the Mandarin Oriental Boston on September 3-4, 2013. The format of the conference will consist of one-on-one meetings and industry panels.

About Coronado Biosciences

Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The company's two principal pharmaceutical product candidates in clinical development are: TSO (Trichuris suis ova or CNDO-201), a biologic for the treatment of autoimmune diseases, including Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer (NK) cells, for the treatment of acute myeloid leukemia (AML), multiple myeloma and solid tumors. For more information, please visit www.coronadobiosciences.com.

CONTACT: Lucy Lu, MD, Executive Vice President & Chief Financial Officer Coronado Biosciences, Inc. 781-652-4525; ir@coronadobio.com Marcy Nanus, Vice President The Trout Group, LLC. 646-378-2927; mnanus@troutgroup.com Susan Forman Dian Griesel Inc. 212-825-3210; susan@dgicomm.com

Source:Coronado Biosciences